Peptide data sheet
Tesamorelin
Recovery · TH9507 · Tesamorelin acetate
Verdict
promisingThe promising label reflects the human trial data behind the branded drug for one narrow use; research-grade tesamorelin sold for lab use is not the same product and has a thinner safety picture.
Quick answer
Tesamorelin is a growth-hormone-releasing factor (GHRH) analog commonly researched for how it affects visceral abdominal fat and the growth-hormone/IGF-1 axis. Unlike most research peptides it has real human trial data: that data supported the branded prescription drug Egrifta, FDA-approved for one narrow use. Research-grade tesamorelin sold for lab use is not that product and is not FDA-approved.
- Class
- GHRH analog (growth-hormone-releasing factor)
- Half-life
- roughly 26 to 38 minutes (reported)
- FDA status
- Egrifta (tesamorelin) is FDA-approved for one narrow use (HIV-associated lipodystrophy). Research-grade tesamorelin sold for lab use is a different product intended for laboratory research only.
- WADA banned?
- Yes
Which form actually works?
Injectable (subcutaneous)
Promising
The form the human trials and the branded prescription drug used. People report the effect timing and the reported side effects here, and it carries the most research context of any form.
Oral or transdermal
Unproven
You will see it pitched as capsules or creams. There is little consistent human data that these routes deliver an intact peptide, so treat those formats as unproven marketing rather than a studied option.